Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago

Deferoxamine Mesylate

Carboxylic acids and derivatives Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Deferoxamine Mesylate is used in acute iron intoxication and in chronic iron overload caused by transfusion-dependent anemias. It is also used in the Deferoxamine Mesylate infusion test, which helps diagnose aluminum overload. And it is used for chronic aluminum overload in patients with End-Stage Renal Failure (ESRF) who are on maintenance dialysis.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Deferoxamine treats iron toxicity by binding trivalent (ferric) iron, which it has a strong affinity for. The two form ferrioxamine, a stable complex that the kidneys remove from the body. 100 mg of deferoxamine can bind approximately 8.5 mg of trivalent (ferric) iron.

In aluminum toxicity, deferoxamine binds aluminum that is held in the tissues and forms aluminoxamine, a stable, water-soluble complex. This raises the concentration of aluminum in the blood, so the gradient between the blood and the dialysate becomes larger and more aluminum is removed during dialysis. 100 mg of deferoxamine can bind approximately 4.1 mg of aluminum.

Pregnancy & Breastfeeding

Pregnant women: There are no adequate and well-controlled studies of deferoxamine in pregnant women. Studies in animals (rabbits) have shown reproductive toxicity, and the risk to the baby or the mother is unknown. Women who could become pregnant and who have chronic iron and/or aluminum overload should not receive deferoxamine unless they use an effective form of contraception. The contraception must be started before treatment and continued throughout treatment and for at least the first month after it. During pregnancy, particularly in the first trimester, deferoxamine should only be used if the danger of acute iron intoxication is thought to be greater than the possible teratogenic danger of deferoxamine.

Nursing women: It is not known whether deferoxamine mesylate passes into breast milk. Many drugs are excreted in human milk, and there is a chance of serious adverse drug reactions in breast-fed newborns and infants. So a decision should be made either to stop breast-feeding or to stop using the medicine, taking into account how important the medicine is to the mother.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Deferoxamine mesylate must be given only by a parenteral route. The dose should not go above 6.0 grams in a twenty-four hour period. It can be given by intramuscular injection, but in most cases it works considerably better as a continuous infusion. That means an intravenous infusion, especially in acute iron intoxication, or a subcutaneous infusion, especially in patients with chronic iron overload. Giving Deferoxamine as a rapid intravenous injection at more than 15 mg/kg/h has caused flushing of the skin, urticaria, hypotension and shock.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.